Statistical Analysis
RECURRENCES
SECRAB was powered only to detect differences in local recurrences rates, the primary outcome. Consequently, the sub-studies were not formally powered, rather it was the aim to use at least 300 patients (150 in each arm) to compare differences in QoL, cosmesis and dose intensity of chemotherapy. The analysis, therefore, is exploratory in nature and no adjustments for multiple testing have been made. In addition, the numbers of patients per arm for each sub-study were not randomised and were instead dependent only on the number of patients who agreed to take part in them.